Objective To investigate the impact of nimodipine and labetalol hydrochloride combined with Danshen injection on serum levels of PGE2 and Apelin, and maternal-infant outcome in patients with pregnancy-induced hypertension. Methods A total of 120 patients with pregnancy-induced hypertension were selected in the Second Affiliated Hospital of Xi'an Medical University from March 2016 to August 2017, and they were divided into control group and study group according to random number table, each of 60 cases. Based on conventional treatment, patients in control group received nimodipine combined with labetalol hydrochloride, while patients in study group received Danshen injection based on that of control group; both groups continuously treated for 10 days. Clinical effects, DBP, SBP, serum levels of PGE2 and Apelin before and after treatment, and incidence of adverse maternal-infant outcome were compared between the two groups.Results Clinical effect in study group was statistically significantly better than that in control group (P<0.05). No statistically significant differences of DBP or SBP was found between the two groups before treatment (P>0.05), while DBP and SBP in study group were statistically significantly lower than those in control group after treatment (P<0.05). No statistically significant differences of serum level of PGE2 or Apelin was found between the two groups before treatment (P>0.05), while serum levels of PGE2 and Apelin in study group were statistically significantly higher than those in control group after treatment (P<0.05). Incidence of adverse maternal-infant outcome in study group was 21.67％, which was statistically significantly lower than that in control group of 38.33％ (P<0.05).Conclusion Nimodipine and labetalol hydrochloride combined with Danshen injection can effectively reduce the blood pressure in patients with pregnancy-induced hypertension, improve the clinical effect, serum levels of PGE2 and Apelin, reduce the risk of adverse maternal-infant outcome.%目的 探讨尼莫地平与盐酸拉贝洛尔联合丹参注射液对妊娠期高血压患者血清前列腺素E2(PGE2)、Apelin水平及母婴结局的影响.方法 选取西安医学院第二附属医院2016年3月—2017年8月收治的妊娠期高血压患者120例,采用随机数字表法分为对照组与研究组,每组60例.在常规治疗基础上,对照组患者给予尼莫地平联合盐酸拉贝洛尔治疗,研究组患者在对照组基础上加用丹参注射液治疗;两组患者均连续治疗10 d.比较两组患者临床疗效,治疗前后舒张压(DBP)、收缩压(SBP)及血清PGE2、Apelin水平,不良母婴结局发生情况.结果 研究组患者临床疗效优于对照组(P<0.05).治疗前两组患者DBP、SBP比较,差异无统计学意义(P>0.05);治疗后研究组患者DBP、SBP低于对照组(P<0.05).治疗前两组患者血清PGE2、Apelin水平比较,差异无统计学意义(P>0.05);治疗后研究组患者血清PGE2、Apelin水平高于对照组(P<0.05).研究组患者不良母婴结局发生率(21.67％)低于对照组(38.33％)(P<0.05).结论 尼莫地平与盐酸拉贝洛尔联合丹参注射液可有效降低妊娠期高血压患者血压,提高临床疗效及血清PGE2、Apelin水平,降低不良母婴结局发生风险.
展开▼
